Generic Name: umeclidinium / vilanterol
Applies to umeclidinium / vilanterol: inhalation powder
In addition to its needed effects, some unwanted effects may be caused by umeclidinium / vilanterol. In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking umeclidinium / vilanterol:
Some of the side effects that can occur with umeclidinium / vilanterol may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:


Applies to umeclidinium / vilanterol: inhalation powder
The most common adverse reaction was nasopharyngitis (9%).[Ref]
Common (1% to 10%): Diabetes Mellitus[Ref]
Common (1% to 10%): Constipation, dry mouth, diarrhea, nausea, abdominal pain, toothacheUncommon (0.1% to 1%): Dyspepsia, gastroesophageal reflux disease, vomiting[Ref]
Common (1% to 10%): Urinary tract infectionFrequency not reported: Signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination)[Ref]
Common (1% to 10%): Pain in extremity, muscle spasms, neck pain, back pain, arthralgiaUncommon (0.1% to 1%): Musculoskeletal chest pain[Ref]
Common (1% to 10%): HeadachePostmarketing reports: Dysgeusia, tremor[Ref]
Common (1% to 10%): VertigoUncommon (0.1% to 1%): Asthenia[Ref]
Common (1% to 10%): Pharyngitis, sinusitis, nasopharyngitis, lower respiratory tract infection, upper respiratory tract infections, cough, chest pain, pleuritic pain, viral respiratory tract infection, oropharyngeal painUncommon (0.1% to 1%): Productive cough, chest discomfortFrequency not reported: Paradoxical bronchospasm[Ref]
Uncommon (0.1% to 1%): Atrial fibrillation, ventricular extrasystoles, supraventricular extrasystoles, myocardial infarction, rhythm idioventricular, tachycardia, supraventricular tachycardiaFrequency not reported: Symptoms of increases in pulse rate, systolic or diastolic blood pressurePostmarketing reports: Palpitations[Ref]
Uncommon (0.1% to 1%): Pruritus, rash[Ref]
Uncommon (0.1% to 1%): ConjunctivitisFrequency not reported: Worsening of narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema)[Ref]
Postmarketing reports: Hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria
Postmarketing reports: Anxiety
1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
2. "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC. 
3. Kelleher DL,  Mehta RS,  Jean-Francois BM, et al. "Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial." PLoS One 7 (2012): e50716
Not all side effects for Anoro Ellipta may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Body aches or pain
chest pain
congestion
cough
dryness or soreness of the throat
fever
headache
hoarseness
pain or tenderness around the eyes and cheekbones
stuffy or runny nose
tender, swollen glands in the neck
tightness of the chest
trouble breathing
trouble swallowing
voice changes


Chest discomfort
dizziness
fainting
fast or irregular heartbeat
nausea
pain or discomfort in the arms, jaw, back, or neck
sweating
vomiting


Diarrhea
difficulty having a bowel movement (stool)
muscle spasms


Acid or sour stomach
belching
burning, dry, or itching eyes
discharge or excessive tearing
dry mouth
heartburn
indigestion
lack or loss of strength
rash or itching skin
redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid
stomach discomfort, upset, or pain

